Cervical Cancer Treatment in India
Get Cervical Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Cervical Cancer Treatment in UAE
Cervical Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Cervical cancer treatment encompasses a spectrum of evidence-based interventions—including radical hysterectomy, concurrent chemoradiation, immunotherapy, and targeted biologics—tailored to tumor stage, histology, and the patient's overall health profile. With five-year survival rates exceeding 90% for early-stage disease at high-volume cancer centers, the outcomes achievable in India and the UAE rival those of Western tertiary institutions at a fraction of the cost. GAF Healthcare connects international patients to JCI- and NABH/DHA-accredited oncology centres in India and the UAE, providing end-to-end coordination from diagnosis confirmation through post-treatment surveillance.
Hospital Stay: 5–14 days (varies by treatment modality: surgery alone vs. combined chemoradiation) • Total Stay in Country (Fit-to-Fly): 3–8 weeks (surgical patients: 4–6 weeks; chemoradiation patients: 6–8 weeks post-treatment completion) • Success Rate: 85–95% (Stage I–IIA); 65–75% (Stage IIB–IIIB); 15–25% (Stage IV)
What Is It?
Cervical cancer arises predominantly from the squamocolumnar junction of the uterine cervix, with over 90% of cases attributable to persistent high-risk Human Papillomavirus (HPV) infection—most commonly HPV genotypes 16 and 18. The two principal histological subtypes are squamous cell carcinoma (~70–75%) and adenocarcinoma (~20–25%), each carrying distinct prognostic implications. Precancerous lesions (CIN I–III / HSIL) detected through colposcopy and biopsy represent the earliest intervention window; invasive disease is staged using the FIGO 2018 classification system, which incorporates imaging findings from MRI, PET-CT, and lymph node assessment to guide treatment decisions.
Physiologically, invasive cervical carcinoma compromises uterine structural integrity, may obstruct the ureters (leading to hydronephrosis and renal impairment), invade the parametria, involve pelvic lymph nodes, or—in advanced disease—metastasize to para-aortic nodes, lung, liver, and bone. Patients may present with abnormal uterine bleeding, post-coital bleeding, malodorous vaginal discharge, pelvic pain, or—in late-stage disease—lower-extremity lymphedema and sciatic-distribution neuropathic pain secondary to lateral pelvic sidewall involvement. Accurate staging via MRI pelvis with contrast and 18F-FDG PET-CT is non-negotiable before finalizing the therapeutic strategy.
The internationally accepted standard of care follows FIGO staging: Stage IA1 disease without lymphovascular space invasion (LVSI) is managed with simple hysterectomy or cervical conisation (fertility-sparing); Stage IA2–IB2 and select IIA1 disease is treated with radical hysterectomy (Wertheim or Type C Querleu-Morrow classification) plus pelvic lymph node dissection, with or without adjuvant chemoradiation based on Sedlis or Peters criteria; and Stage IB3 and above is managed with concurrent platinum-based chemoradiation (external beam radiotherapy plus brachytherapy) as the definitive backbone. Immunotherapy with pembrolizumab (anti-PD-1) is now incorporated into first-line therapy for PD-L1–positive recurrent or metastatic disease, following the KEYNOTE-826 trial data.
Candidates
• ELIGIBLE PATIENTS:
• Women diagnosed with cervical cancer at any FIGO stage (IA1 through IVA/IVB) seeking curative or palliative treatment
• Patients with confirmed HPV-related squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
• Women with recurrent or refractory cervical cancer following prior treatment, seeking second-line systemic therapy or palliative options
• Patients seeking fertility-preserving surgery (radical trachelectomy) for Stage IA2–IB1 disease with tumour ≤2 cm and no lymph node involvement
• International patients requiring multidisciplinary tumour board review and treatment planning before commencing therapy in their home country
• REQUIRED PRE-TREATMENT DIAGNOSTICS:
• Colposcopy-directed biopsy or LLETZ/LEEP cone biopsy with histopathological reporting including LVSI status
• MRI pelvis and abdomen with gadolinium contrast (parametrial assessment, tumour dimensions, bladder/rectal involvement)
• 18F-FDG PET-CT (whole body) for lymph node mapping and distant metastasis exclusion
• Complete blood count (CBC), comprehensive metabolic panel (CMP), renal function tests, liver function tests
• HPV genotyping and p16/Ki-67 immunohistochemistry
• PD-L1 Combined Positive Score (CPS) testing if metastatic/recurrent disease is confirmed (for pembrolizumab eligibility)
• HER2 status testing for adenocarcinoma subtype (emerging relevance)
• Transvaginal ultrasound and examination under anaesthesia (EUA) if parametrial status remains equivocal
• Renal function and GFR assessment prior to cisplatin-based chemotherapy
• Pulmonary function tests if thoracic radiation is considered
• Fertility preservation consultation (ovarian transposition, embryo/oocyte cryopreservation) for premenopausal patients undergoing pelvic radiation
• RELATIVE CONTRAINDICATIONS / COMPLICATING FACTORS:
• Uncontrolled medical comorbidities (severe cardiac failure, ECOG performance status ≥3) that preclude surgery or systemic therapy
• Prior pelvic radiation (bowel/bladder tolerance constraints limit re-irradiation options)
• Active autoimmune conditions requiring immunosuppressive therapy (relative contraindication to immunotherapy/pembrolizumab)
• Severe renal impairment (eGFR <40 mL/min) limiting cisplatin use; carboplatin substitution may be considered
• Pregnancy (requires multidisciplinary planning; treatment may be deferred to second/third trimester or modified)
• Confirmed stage IVB with poor performance status where aggressive treatment would not alter prognosis
Procedure
SURGICAL APPROACHES:
1. Radical Hysterectomy (Type B/C Querleu-Morrow / Wertheim Procedure): The gold-standard surgical intervention for Stage IA2–IB2 and select IIA1 cervical cancer. Involves en-bloc removal of the uterus, cervix, upper vaginal cuff (1–2 cm), parametrial tissue, and pelvic lymph node dissection (obturator, internal/external iliac, common iliac). Nerve-sparing variants (Type C1) preserve the inferior hypogastric plexus, significantly reducing bladder and bowel dysfunction compared to the classical non-nerve-sparing (Type C2) approach.
2. Minimally Invasive Radical Hysterectomy (Robotic / Laparoscopic): Robotic-assisted radical hysterectomy using the da Vinci Xi Surgical System offers a 3D operative field, 7-degrees-of-freedom instrument articulation, and magnified visualisation. However, following the LACC Trial (2018), open abdominal radical hysterectomy (OAR) remains the preferred approach for invasive disease due to superior disease-free and overall survival data. Robotic/laparoscopic approaches may be reserved for highly selected cases or clinical trials. Leading centres in India and the UAE adhere strictly to this evidence-based guideline.
3. Radical Trachelectomy (Fertility-Sparing): For Stage IA2–IB1 disease (tumour ≤2 cm, no lymph node involvement), radical trachelectomy with pelvic lymph node dissection preserves the uterine body and ovarian function, enabling future pregnancy. Available in both abdominal and vaginal (Dargent) approaches. Pregnancy rates post-trachelectomy range from 40–70% in published series.
4. Pelvic Exenteration: Reserved for centrally recurrent cervical cancer without sidewall involvement. Anterior exenteration (bladder removal), posterior exenteration (rectal removal), or total pelvic exenteration with urinary and fecal diversion. A highly specialised, resource-intensive procedure available at select tertiary oncology centres in India (e.g., Tata Memorial Hospital, Apollo Cancer Centres) and the UAE (Cleveland Clinic Abu Dhabi, American Hospital Dubai).
RADIATION-BASED APPROACHES:
5. External Beam Radiotherapy (EBRT) with Intensity-Modulated Radiation Therapy (IMRT) / Volumetric Modulated Arc Therapy (VMAT): Modern radiation planning using IMRT/VMAT delivers highly conformal radiation to the cervix, parametria, and nodal regions while sparing the rectum, bladder, and bowel. Total dose: 45–50.4 Gy in 25–28 fractions over 5 weeks, concurrent with weekly cisplatin 40 mg/m².
6. Image-Guided Adaptive Brachytherapy (IGABT): Following EBRT, high-dose-rate (HDR) intracavitary or combined intracavitary/interstitial brachytherapy using MRI-guided applicators (ring-and-tandem, Vienna applicator, Utrecht applicator) boosts the primary tumour to a cumulative Equivalent Dose in 2Gy fractions (EQD2) of ≥85–90 Gy for the high-risk Clinical Target Volume (HR-CTV). This GEC-ESTRO protocol-driven approach is now the worldwide standard, demonstrating local control rates of 85–95% for FIGO IB–IIB disease.
7. Stereotactic Body Radiotherapy (SBRT) / CyberKnife: Used for oligometastatic disease, para-aortic nodal boost, or palliative intent in selected patients with limited metastatic sites.
SYSTEMIC THERAPY:
8. Concurrent Chemoradiation (CRT): Platinum-based (cisplatin 40 mg/m² weekly) concurrent with EBRT remains the definitive systemic backbone for locally advanced disease (Stage IB3–IVA). Bevacizumab (anti-VEGF) is added in the metastatic setting based on GOG-0240 trial data.
9. Immunotherapy — Pembrolizumab (Keytruda): FDA and USFDA-approved for PD-L1–positive (CPS ≥1) persistent, recurrent, or metastatic cervical cancer. The KEYNOTE-826 trial demonstrated significant improvement in overall survival when pembrolizumab was added to chemotherapy ± bevacizumab. Also approved as monotherapy (CPS ≥10) for TMB-high disease.
10. Targeted Therapy — Bevacizumab (Avastin): Anti-angiogenic agent combined with paclitaxel/cisplatin or paclitaxel/topotecan for recurrent/metastatic disease; improves median OS by ~3.5 months (GOG-0240 data).
11. Antibody-Drug Conjugates (ADCs): Tisotumab vedotin (Tivdak), an anti-Tissue Factor ADC, is approved for recurrent/metastatic cervical cancer after prior therapy (innovaTV 204 trial). Represents the newest class of precision-targeted agents available at leading centres.
12. Chemotherapy Regimens for Recurrent/Metastatic Disease: Paclitaxel + Cisplatin + Bevacizumab ± Pembrolizumab; Carboplatin + Paclitaxel (cisplatin-ineligible patients); Topotecan + Paclitaxel; Gemcitabine-based regimens in later lines.
Cost of Cervical Cancer Treatment: India vs. UAE
The cost of cervical cancer treatment varies significantly depending on the treatment modality (surgery alone, chemoradiation, immunotherapy, or combined approaches), the stage of disease, and the destination. India offers world-class oncology care at 40–60% lower cost than the UAE due to lower institutional overheads and procedural costs, without compromising on technology or clinical expertise. The UAE, particularly Dubai and Abu Dhabi, offers premium hospital environments, cutting-edge infrastructure, and seamless access for patients from the GCC, Africa, and Europe. Both destinations provide access to JCI-accredited institutions with internationally trained oncologists.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $4,000 – $18,000 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $10,000 – $40,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL PLANNING (2–4 weeks before travel):
• GAF Healthcare case manager reviews existing biopsy reports, imaging, and medical records with the destination oncology team
• Multidisciplinary Tumour Board (MDT) review is scheduled; written treatment recommendation sent to the patient within 48–72 hours
• Pre-travel diagnostics checklist issued; any outstanding investigations (PET-CT, MRI) are either facilitated locally or arranged at the destination hospital
• e-Medical Visa (India) or UAE entry documentation assistance initiated; travel and accommodation for patient and one attendant arranged
• Anaesthesia pre-assessment questionnaire and cardiac clearance initiated if surgery is planned
PHASE 2 — ARRIVAL & INSTITUTIONAL WORKUP (Days 1–3):
• Airport transfer to hospital-affiliated accommodation or direct admission
• Oncologist consultation, clinical examination, and review of all imaging
• Any outstanding staging investigations completed: MRI, PET-CT, blood panels, HPV genotyping, PD-L1 CPS testing
• Final MDT meeting; treatment plan confirmed and explained to patient in their language via dedicated GAF interpreter
• Anaesthesia assessment and surgical consent (if applicable); fertility preservation consultation if relevant
• Nutritional optimisation and pre-habilitation counselling initiated
PHASE 3A — SURGICAL TREATMENT PATHWAY (Days 3–7 to 10):
• Day 3–4: Radical hysterectomy with pelvic lymph node dissection (open abdominal approach; duration 3–5 hours)
• ICU or high-dependency unit (HDU) observation for 12–24 hours post-operatively
• Day 1–3 post-op: Urinary catheter, drain management, early ambulation with physiotherapy, DVT prophylaxis (LMWH)
• Day 3–5 post-op: Oral diet reintroduced, catheter removal with bladder training, drain removal
• Day 5–7 post-op: Wound review, discharge to accommodation; outpatient follow-up visits on Days 10 and 14
• Day 14–21 post-op: Final pathology review; adjuvant chemoradiation decision based on Sedlis or Peters criteria (parametrial involvement, positive margins, positive nodes)
• Week 4–6: Fit-to-fly assessment; if adjuvant therapy not required locally, patient cleared for repatriation with detailed oncology discharge summary
PHASE 3B — CHEMORADIATION TREATMENT PATHWAY (Days 3–42 approx.):
• Days 3–5: Simulation CT with IV contrast, target volume delineation by radiation oncologist and physicist; IMRT/VMAT plan generation and quality assurance
• Day 7 onwards: Daily EBRT fractions (Monday–Friday) for 25–28 fractions over 5 weeks; weekly cisplatin infusions on Days 1, 8, 15, 22, 29 (40 mg/m²)
• Weeks 1–5: Weekly toxicity assessments (haematological, renal, GI, skin); anti-emetic, hydration, and haematopoietic growth factor support as needed
• Week 5–6: HDR brachytherapy; typically 4–6 fractions (6–7 Gy per fraction) given twice weekly using MRI-guided IGABT applicators under conscious sedation or general anaesthesia
• End of Week 6–7: Treatment completion; acute toxicity management; response assessment MRI scheduled for Week 8–12
• Week 7–8: Discharge planning; fit-to-fly assessment after haematological recovery; long-term surveillance schedule (3-monthly for first 2 years) provided
PHASE 4 — LONG-TERM FOLLOW-UP (Remote):
• GAF Healthcare facilitates telemedicine follow-up with treating oncologist at 3, 6, and 12 months
• PET-CT or MRI surveillance coordinated locally or at the treating institution
• Survivorship care plan: psychosexual counselling, lymphedema management, hormonal replacement therapy (if ovaries removed) coordinated with the patient's home-country physician
Risks & Considerations
Cervical cancer treatment carries procedure-specific risks that patients must be counselled on explicitly before commencing therapy. Radical hysterectomy carries intraoperative risks including haemorrhage (major vessel injury, estimated blood loss 500–1500 mL), ureteric injury (incidence 1–2%), bladder injury (1–2%), and bowel injury (<1%). Post-operative risks include vesicovaginal fistula formation (1–3%), urinary retention or bladder dysfunction (10–30% for Type C non-nerve-sparing, <10% for nerve-sparing technique), pelvic lymphocele (5–15%), deep vein thrombosis and pulmonary embolism (mitigated by LMWH prophylaxis and early mobilisation), and wound infection. Concurrent chemoradiation with cisplatin introduces haematological toxicity (Grade 3–4 neutropenia in 10–20% of patients), nephrotoxicity (cumulative cisplatin dose must be monitored with weekly renal function tests), significant nausea and vomiting, radiation dermatitis, acute radiation proctitis (diarrhoea, rectal bleeding) and cystitis. Long-term radiation sequelae include radiation proctitis or colitis (5–10%), radiation cystitis (3–8%), vaginal stenosis (highly prevalent without active dilation therapy), premature menopause (in pre-menopausal patients unless ovarian transposition is performed), and secondary malignancy risk (small but definitive). Brachytherapy carries additional risk of applicator-related trauma, fistula formation (vesicovaginal or rectovaginal, <3% in experienced centres using MRI guidance), and parametrial fibrosis. Immunotherapy with pembrolizumab introduces immune-related adverse events (irAEs) including pneumonitis, colitis, hepatitis, endocrinopathies (thyroiditis, adrenal insufficiency), and, rarely, myocarditis—each requiring vigilant monitoring and early corticosteroid intervention. Tisotumab vedotin is associated with peripheral neuropathy, ocular toxicity (conjunctivitis, corneal adverse events requiring prophylactic eye drops), and alopecia. All risks are mitigated by high-volume specialist teams, multidisciplinary toxicity monitoring, and institutional protocols at the GAF Healthcare partner centres.
Top Hospitals for Cervical Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Cervical Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — Cervical Cancer Treatment
The cost of cervical cancer treatment varies significantly between India and the UAE based on the treatment modality, stage of disease, and the specific hospital chosen. In India, the total cost for surgical treatment (radical hysterectomy with lymph node dissection) typically ranges from USD 4,000 to USD 10,000, while a full course of concurrent chemoradiation—including external beam radiotherapy, brachytherapy, and weekly cisplatin chemotherapy—ranges from USD 5,000 to USD 15,000. Combined surgery plus adjuvant chemoradiation may cost USD 10,000–18,000. Immunotherapy courses (pembrolizumab) or advanced biologic agents (bevacizumab, tisotumab vedotin) add to costs based on the number of cycles required. In the UAE (Dubai or Abu Dhabi), the same treatment modalities cost approximately USD 10,000–40,000, with surgical procedures ranging from USD 10,000–20,000 and chemoradiation courses from USD 18,000–35,000. India is consistently 40–60% more affordable than the UAE. However, the UAE offers premium hospital infrastructure, luxury recovery environments, and ease of access for patients from the GCC, Africa, and Europe. Both destinations provide JCI-accredited oncology facilities with internationally trained specialists. GAF Healthcare provides transparent cost estimates inclusive of hospital fees, surgeon fees, standard medications, diagnostics, and accommodation for one attendant before you commit to travel.
The minimum required stay depends on the treatment modality. For patients undergoing radical hysterectomy (surgical treatment only) without complications, the hospital stay is typically 5–10 days, after which approximately 2–4 additional weeks of local recovery are recommended before a long-haul international flight is considered safe. The primary concerns before flying are: complete wound healing, restoration of bladder function (catheter removal and bladder training completed), normalisation of haematological parameters, and DVT risk reduction. Most surgical patients are cleared to fly at approximately 4–6 weeks post-operatively with prophylactic anticoagulation for the flight. For patients completing a full concurrent chemoradiation course (EBRT plus brachytherapy, total 6–7 weeks), the hospital/clinic-based treatment phase itself requires a stay of 6–7 weeks. After treatment completion, a further 1–2 weeks are recommended for acute toxicity resolution (haematological recovery, bowel and bladder symptom stabilisation) before long-haul travel. These patients should expect a total country stay of 7–9 weeks. Patients receiving immunotherapy or systemic therapy in cycles typically require 3-weekly visits for infusion and are managed on a cycle-by-cycle basis. GAF Healthcare provides a personalised fit-to-fly certificate and discharge planning document for every patient, coordinated with the treating oncologist.
Success rates for cervical cancer treatment are strongly stage-dependent and should be interpreted with reference to the specific FIGO stage, histological subtype, and treatment modality. At JCI-accredited high-volume cancer centres in India and the UAE partnered with GAF Healthcare, published and reported five-year survival rates are: Stage IA (micro-invasive): 95–98% with surgical treatment; Stage IB1–IB2: 85–92% with radical hysterectomy or definitive chemoradiation; Stage IIA: 75–85% with combined modality treatment; Stage IIB: 65–75% with concurrent chemoradiation; Stage IIIA–IIIB: 40–65% with concurrent chemoradiation and modern IMRT/IGABT brachytherapy; Stage IVA (localised pelvic metastasis): 15–30%; Stage IVB (distant metastasis): Median overall survival has improved to 17–24 months with the addition of pembrolizumab immunotherapy to platinum-based chemotherapy in PD-L1 positive patients (KEYNOTE-826 data). Local control rates for Stage IB–IIB cervical cancer treated with MRI-guided image-guided adaptive brachytherapy (IGABT) following IMRT reach 85–95% at three years, based on GEC-ESTRO EMBRACE study data replicated at leading centres. These figures are benchmarked against international datasets and reflect outcomes achievable at the specific high-volume oncology institutions in GAF Healthcare's partner network, which include institutions performing 200–500+ cervical cancer cases annually.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical coordination for international patients travelling to India or the UAE for cervical cancer treatment.
INDIA LOGISTICS:
• e-Medical Visa (e-MV) Application: GAF Healthcare prepares and submits the patient's e-Medical Visa application on their behalf, including hospital invitation letters, diagnosis documentation, and financial undertaking. The e-MV is valid for 60 days with two permitted extensions, allows two accompanying attendants on e-Medical Attendant Visas, and is typically approved within 1–4 business days.
• Airport Transfers: Private ambulance or executive vehicle transfers arranged between international arrival airports (Indira Gandhi International Delhi, Chhatrapati Shivaji Maharaj International Mumbai, Kempegowda International Bengaluru, Rajiv Gandhi International Hyderabad) and partner hospitals or affiliated serviced apartments.
• Dedicated Case Manager: A single point of contact fluent in English and the patient's native language is assigned for the entire treatment episode, coordinating between the oncology team, diagnostic departments, pharmacy, and accommodation.
• Certified Medical Interpreters: Available for Arabic, Russian, French, Swahili, Amharic, Uzbek, Bangla, and other languages, present during all consultations, consent discussions, and treatment briefings.
• Attendant Accommodation: Hospital guest houses, affiliated service apartments, or partner hotels within 1–3 km of the treatment centre are arranged for up to two accompanying family members at negotiated rates (USD 30–80 per night depending on city and standard).
• Telemedicine Pre-Travel Consultation: Secure video consultation with the treating oncologist arranged before travel to confirm treatment suitability and answer patient questions.
UAE LOGISTICS:
• Visa Facilitation: Citizens of over 50 countries receive visa-on-arrival or visa-free entry to the UAE for 14–90 days. GAF Healthcare provides formal hospital appointment letters to support visa applications for nationalities requiring advance authorisation. Medical tourism visas are also facilitated through Dubai Health Authority (DHA) and Abu Dhabi Health Services Company (SEHA) partner channels.
• Airport Transfers: Private executive vehicle or medical transport arranged from Dubai International Airport (DXB), Abu Dhabi International Airport (AUH), or Al Maktoum International (DWC) to partner hospitals including Cleveland Clinic Abu Dhabi, American Hospital Dubai, Mediclinic City Hospital, and King's College Hospital Dubai.
• Premium Accommodation: Hotel apartments and serviced residences adjacent to JCI/DHA-accredited hospitals arranged for patient and attendants, including options with hospital-grade accessibility features.
• Insurance Liaison: GAF Healthcare liaises with international health insurance providers and TPA companies to obtain pre-authorisation letters for treatment at UAE partner hospitals.
• Interpreter Services: Arabic is the primary clinical language; English is universally spoken by all medical staff at partner hospitals. Additional languages (Russian, French, Hindi, Urdu, Tagalog) supported through the GAF Healthcare interpreter network.
• Post-Treatment Concierge: Optional extended recovery packages including physiotherapy, nutritional counselling, and wellness services arranged at partner facilities or luxury recovery residences in Dubai or Abu Dhabi.
Patients Also Explore
Other treatments commonly sought by patients considering Cervical Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology